fashion -WSS

fashion

author：entertainment 2025-09-30 12:17:25 - browse：767

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： Activists slam private health insurers over coverage restrictions
Next article： ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

WSS

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

STAT Readout Newsletter: Today in biotech, life science news

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

How doctors and nurses shape Google's AI

Bernie Sanders bashes nonprofit hospitals over their tax breaks

focus

fashion

Sign up for Morning Rounds

knowledge

Tori Bowie and the unacceptable rates of Black maternal death

Cancer cells are shown to suck energy source from immune cells

Wildfire smoke exposes gaps in outdoor worker protections

Cord blood banking comes at a high cost to babies

Medical leaders decry Supreme Court decision on affirmative action

European regulators consider appeal over Amylyx ALS drug

Peter Hotez and the public health issue of online harassment

HIV drugs protect against transmission, even in unprotected sex

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Intellia reports positive results for its CRISPR

focus

Bernie Sanders bashes nonprofit hospitals over their tax breaks

At ASCO, AstraZeneca reports strong data for breast cancer drug

What's changing in Medicare's open enrollment this year?

Medicare to cover more brain scans related to Alzheimer’s drugs

HIV drugs protect against transmission, even in unprotected sex

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

hotspot

focus

entertainment

entertainment